Gibson: Traditional life sciences investors value single assets over platforms
Chris Gibson · 632: Recursion enzyme company raises $23M, launched in 2013 now 40 people with drugs ready for market with CEO Christopher Gibson · Apr 17, 2017 · at 11:27
Chris Gibson, CEO of Recursion Pharmaceuticals, explains why platform biotech companies struggle with traditional biotech VCs and turn to tech investors.
0:00 / 0:23exact quote · 23.4s
720p mp4 · rendered on demand · StarZero watermark
“So we are a platform company, and in our particular space, that's in life sciences, that's actually not the language that people speak in terms of value. They speak in terms of assets. And so that was one of the real challenges for us in terms of raising money initially and why we ended up bringing in our series A investors almost all tech investors who are coming into the space of biology”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Chris Gibson
Gibson: Recursion partnered with Sanofi Genzyme to repurpose shelved drugs
“We've announced, for example, a partnership with Sanofi Genzyme, and in that particular case, we have drugs that, that they spent decades working on in many cases, and those drugs never ended up making it to patients, not because they're bad drugs, just becaus…”
Gibson: Recursion is eight months from clinical trials for CCM
“We also have an internal pipeline of drugs that we're developing ourselves one of those is just about eight months away from clinical trials now for a disease called cerebral cavernous malformation.”
Gibson: Recursion is negotiating eight-figure upfront biotech partnership deals
“And then there's partnerships we're negotiating now that are eight figures upfront.”
Gibson: Recursion raised $19M in equity and $5-6M in non-dilutive grants
“Yeah, we've raised about nineteen million dollars in, in equity financing, and then another five or six million in sort of non-dilutive funds from small business grants from the NIH, and then a number of private foundations as well.”